Jump to content

Draft:Somatic Genetic Engineering

From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Katelynj345 (talk | contribs) at 17:25, 25 April 2025. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Introduction –

Somatic gene engineering is a field of genetic modification involving the alteration of genes of somatic [non-reproductive] cells in a living organism [1]. Unlike germline engineering (which targets the sperm and egg) somatic engineering will not impact future generations. Somatic engineering focuses on modifying cells within the body that do not contribute to inheritance. This technology is very promising for treating genetic disorders, enhancing therapeutic interventions, and improving tissue regeneration [2].

History –

Gene therapy dates back to the early 1970’s, then researchers started looking into the potential alteration of genes to treat disease [3]. They developed recombinant DNA technologies with the ability to cut and paste DNA from different organisms. Early research looked at germline gene editing, then due to ethical concerns and technical challenges, it shifted to somatic gene engineering as somatic engineering was far less controversial. In the 1980’s scientists first started experimenting with gene therapy, as they tried to introduce functional genes into somatic cells to correct genetic disorders [4]. The first trials were conducted in the 1990’s when the FDA approved trials for treating SCID (severe combined immunodeficiency) in children [5]. This trial was done on Ashanti DeSilva and involved removing white blood cells and replacing them with modified cells. It was successful in reducing symptoms and allowed her to attend school. This was a major milestone, but initial trials faced many challenges [6]. Today trials are much safer and more efficient [7].

Applications –

Somatic gene engineering has many potential applications. Some are: 1. Gene Therapy for Genetic Disorders One of the most promising uses of somatic gene engineering is treatment for genetic disorders (like cystic fibrosis, muscular dystrophy, and sickle cell anemia) [8]. This can be done by the introduction of functional genes, which should compensate for the defective or missing genes. This will alleviate some of the symptoms or may even cure the condition [9]. 2. Cancer Treatment Gene engineering has been explored as a treatment method for cancer. For this researcher aimed to modify immune cells (like T-cells) to target and destroy cancer cells more effectively. This approach is called gene-modified immunotherapy or CAR-T therapy. It has shown to be effective for blood such as Leukemia or lymphoma [10]. 3. Regenerative Medicine Somatic gene engineering shows significant promise in regenerative medicine, where genes can be edited to promote tissue repair or regeneration [11]. This can be used in the treatment of heart disease, spinal cord injuries, and liver cirrhosis, as well as man other conditions. It works by stimulating growth of healthy cells to repair damaged tissues [12]. 4. Infectious Disease Another potential application is gene editing to eliminate viruses. This is the treatment of infectious diseases and could be used for HIV or hepatitis treatments. It uses gene editing technologies like CRISPR to eliminate a virus from an infected cell [13].

Methods of Somatic Gene Engineering –

Somatic gene engineering relies on a technique to deliver and insert new genetic material into a targeted cell. Some things used to do this are viral vectors, non-viral vectors, or CRISPR-Cas9. Viral vectors are modified to be harmless and are used to deliver new genes into a somatic cell [14]. The virus enters a target cell as it typically would then integrates the genetic material it carries into the cell. The genetic material has been modified to what we want it to function as (like to produce a therapeutic protein or to replace a defective gene). Non-Viral Vectors are things like electroporation, lipid nanoparticles or be a physical technique [15]. These methods are safer, but they are less efficient than the viral method. CRISPR-Cas9 is a new technology that allows for precise and targeted editing of the genome. CRISPR is used to cut DNA at a specific location, then enabling the insertion of correct gene [16]. CRISPR has very high accuracy and has recently become a key tool in research.

Challenges –

Somatic gene engineering faces several challenges that can make it unsafe and non-effective. Some of these challenges are delivery efficiency. This is a main obstacle as therapeutic genes need to reach the target cell to incorporate into the genome and improve function [17]. The efficiency of gene delivery is a highly intense realm of research and people are always working to improve it [18]. Another challenge is the immune system response. As foreign genes are introduced it can provoke an immune response which can reduce the effectiveness of the treatment as well as causing harmful side effects [19]. Researchers are looking for ways to minimize the immune reaction like the non-viral delivery method. Long-term effects like safety and efficacy are still uncertain. Early results appeared promising, but we still do not know the long-term effects like unintended genetic changes, cancer risks, or immune tolerance [20]. The last major challenge is ethical and regulatory issues. These are centered around safety, consent, and access to treatment. Regulatory bodies are working to set clear guidelines, but this takes time with patient safety and long-term monitoring.

Future Directions –

The future of somatic gene engineering is looking promising with many advancements being made in gene editing technologies, better delivery systems, and a growing understanding of gene therapy’s applications [21]. Professionals continue to work on expanding its involvement in medicine, using precise methods to treat many diseases [22]. If these methods are successful, relief can be offered to many patients and their families. Ongoing clinical trials also continue to test for safety and efficacy of somatic therapies, with several therapies already approved [23]. There is continued collaboration between researchers, healthcare professionals, and policy makers addressing the challenges as well as looking for the full potential of somatic engineering [24]. However, because there are still many concerns and disagreements involved with current animal studies, human studies have many risks [25].

Also See –

- Gene therapy

- CRISPR – Ca9

- Gene Editing

- Regenerative Medicine

- Stem Cell Therapy

References

  1. ^ Saha, Krishanu, et al. “The NIH Somatic Cell Genome Editing Program.” Nature News, Nature Publishing Group, 7 Apr. 2021, www.nature.com/articles/s41586-021-03191-1.
  2. ^ Johnson, Emily, et al. “Somatic Genome Editing: An Overview.” PHG Foundation, 29 Aug. 2024, www.phgfoundation.org/publications/policy-briefings/somatic-genome-editing-overview/.
  3. ^ Sciences, National Academies of, et al. “Somatic Genome Editing.” Human Genome Editing: Science, Ethics, and Governance., U.S. National Library of Medicine, 14 Feb. 2017, www.ncbi.nlm.nih.gov/books/NBK447271/.
  4. ^ (Johnson)
  5. ^ Cavazzana-Calvo, M., et al. (2000). Gene Therapy for Severe Combined Immunodeficiency. New England Journal of Medicine, 342(9), 669-680.
  6. ^ Junghyun Ryu Ph.D. a, et al. “The History, Use, and Challenges of Therapeutic Somatic Cell and Germline Gene Editing.” Fertility and Sterility, Elsevier, 5 Mar. 2023, www.sciencedirect.com/science/article/pii/S0015028223001735.
  7. ^ (Johnson)
  8. ^ (Johnson)
  9. ^ (Junghyun)
  10. ^ (Somatic Genome Editing)
  11. ^ (Johnson)
  12. ^ (Somatic Genome Editing)
  13. ^ Anderson, W. F., et al. (2014). Gene Therapy: A New Era in Medicine. Annual Review of Medicine.
  14. ^ (Anderson)
  15. ^ Bergman, Mary Todd. “Harvard Researchers Share Views on Future, Ethics of Gene Editing.” Harvard Gazette, 10 Jan. 2024, news.harvard.edu/gazette/story/2019/01/perspectives-on-gene-editing/. Accessed 23 Mar. 2025.
  16. ^ (Johnson)
  17. ^ (Johnson)
  18. ^ Porteus, M. H., & Carroll, D. (2005). Gene Therapy: Targeted Gene Editing. Nature Reviews Genetics, 6(6), 411-423.
  19. ^ (Cavazzana-Calvo)
  20. ^ (Bergman)
  21. ^ (Porteus)
  22. ^ (Somatic Genome Editing)
  23. ^ (Somatic Genome Editing)
  24. ^ (Saha)
  25. ^ (Bergman)